Ascites Market Synopsis

According to a new report published by Introspective Market Research, titled, “Ascites Market by Type, Diagnosis, Treatment, End-Users, and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2024–2032,” 

Global Ascites market size was valued at $ 1.72 Billion in 2023, and is projected to reach $ 2.41 Billion by 2032, registering a CAGR of 3.8 % from 2024 to 2032.

The ascites market is the healthcare industry that deals with the diagnosis, treatment, and management of ascites, a disorder marked by the build-up of fluid in the abdominal cavity. This market encompasses medications, medical equipment, and diagnostic instruments designed to treat the symptoms and underlying causes of ascites, which are frequently associated with liver cirrhosis, heart failure, or cancer. It is an important area of focus for healthcare providers and pharmaceutical businesses since ascites can cause major consequences and have a considerable influence on patients' quality of life. Continuous research and innovation promote breakthroughs in ascites management.   

The global ascites market was expanding because of the increasing prevalence of illnesses that can cause ascites, such as liver cirrhosis, heart failure, and certain malignancies. Liver cirrhosis, which is frequently related with excessive alcohol intake and viral hepatitis, continues to be a major cause of ascites all over the world. With changing lifestyles and a global increase in obesity and alcohol consumption, the incidence of liver cirrhosis and, consequently, ascites has increased.  

Excessive alcohol intake remains a major contributor to the increased incidence of liver cirrhosis. Chronic alcohol usage can result in alcoholic liver cirrhosis, which is defined by scarring of the liver tissue. The global availability of alcohol and changing drinking habits have increased alcohol-related liver illnesses. Furthermore, unhealthy lifestyles characterized by poor food choices, sedentary behaviors, and obesity have been linked to non-alcoholic fatty liver disease (NAFLD), which can progress to cirrhosis with time. The increase in these risk factors has caused a surge in cirrhosis cases.

Technological advancements have resulted in more precise and non-invasive diagnostic tools, such as sophisticated imaging techniques and biomarker analysis. Early identification of ascites enables timely intervention and care, slowing the course of the underlying diseases and improving patient outcomes. This is an opportunity to improve patient care while potentially lowering the economic burden of advanced illness management. Modern technology enables a more tailored approach to treatment. The capacity to precisely determine the origin and severity of ascites allows healthcare practitioners to personalize therapies to each patient's needs.

Global Ascites Market, Segmentation

The Ascites market is segmented on the basis of Type, Diagnosis, Treatment, End-Users, Distribution Channel, and region.

Type:

The type segment is further classified into Transudative and Exudative. Among these, the Transudative sub-segment accounted for the highest market share in 2023. The term "transudative" refers to a specific type of fluid collection in the abdominal cavity called ascites. Transudative ascites are defined by the presence of clear, straw-colored fluid in the abdominal cavity. This type of ascites is primarily caused by non-inflammatory diseases, which are frequently linked to systemic disorders such as liver cirrhosis, heart failure, or hypoalbuminemia. The underlying cause of transudative ascites is an imbalance in fluid and protein distribution in the body, resulting in the accumulation of this clear fluid in the peritoneum.

End-Users:

The End-Users segment is further classified into Hospitals and Clinics, Homecare, and Specialty Clinics. Among these, the Hospitals and Clinics sub-segment is anticipated to show the fastest growth by 2032. Hospitals and clinics are the primary healthcare facilities where people with ascites seek medical attention and treatment. Ascites are frequently an indication of an underlying medical issue, such as liver cirrhosis or heart failure, necessitating expert medical treatment and diagnosis. Hospitals and clinics are outfitted with cutting-edge diagnostic equipment, medical personnel, and specialized departments such as gastroenterology and hepatology, all of which are critical for accurately identifying and managing ascites.

Region:

The Ascites market in North America is projected to show the fastest growth by 2032. The region has a high incidence of liver cirrhosis, which is one of the most common underlying causes of ascites. Liver cirrhosis is frequently caused by prolonged alcohol intake and other liver illnesses, and it can result in fluid collection in the abdominal cavity, known as ascites. North American lifestyle and nutritional habits have contributed to a higher incidence of liver cirrhosis, necessitating the identification and treatment of ascites. This high prevalence of cirrhosis drives the regional ascites market, as healthcare practitioners and consumers seek better diagnostic and therapy options to manage this illness.

Some of the leading Ascites market players are

• PharmaCyte Biotech (USA)
• Eli Lilly and Company (USA)
• Pfizer (USA)
• Merck (USA)
• BioVie USA
• Johnson & Johnson Private Limited (USA)
• BD (Becton, Dickinson and Company) (USA)
• GI Supply (USA)
• Mylan (USA)
• GE (General Electric) (USA), and Other Active Players.

Key Industry Developments

• In April 2024, Eli Lilly and Company and Nexus Pharmaceuticals, LLC announced that they had entered into a definitive agreement for Lilly to acquire a manufacturing facility from Nexus, a leading sterile manufacturer in the pharmaceutical industry. The acquisition of this FDA-approved facility in Pleasant Prairie, Wisconsin, was set to further expand Lilly's global parenteral (injectable) product manufacturing network and support increased demand for the company's medicines. Lilly estimated that production at this facility could begin at the end of 2025.
• In December 2023, Pfizer Inc. announced the successful completion of its acquisition of Seagen Inc. a global biotechnology company that discovers, develops, and commercializes transformative cancer medicines. Pfizer completed the acquisition of all outstanding common stock of Seagen for $229 in cash per share, resulting in a total enterprise value of approximately $43 billion.

Key Findings of the Study / Key Industry Developments. 

• The rising incidence of liver cirrhosis, driven by excessive alcohol intake and viral hepatitis, and advancements in diagnostic tools are significant market drivers.
• Transudative ascites held the highest market share in 2023 within the type segment.
• The hospitals and clinics end-user segment is anticipated to experience the fastest growth by 2032.